primaryid int64 82.9M 2.23B | caseid int64 8.29M 23.4M | caseversion int64 1 47 | i_f_code stringclasses 2
values | event_dt float64 20M 20.2M ⌀ | mfr_dt float64 20.2M 20.2M ⌀ | init_fda_dt stringdate 2011-12-14 00:00:00 2023-12-31 00:00:00 | fda_dt stringdate 2023-01-02 00:00:00 2023-12-31 00:00:00 | rept_cod stringclasses 5
values | auth_num stringclasses 98
values | mfr_num stringlengths 13 54 ⌀ | mfr_sndr stringclasses 138
values | lit_ref stringclasses 81
values | age float64 0 24.3k ⌀ | age_cod stringclasses 4
values | age_grp stringclasses 6
values | sex stringclasses 3
values | e_sub stringclasses 2
values | wt float64 2 245 ⌀ | wt_cod stringclasses 2
values | rept_dt stringdate 2022-12-21 00:00:00 2023-12-31 00:00:00 | to_mfr stringclasses 2
values | occp_cod stringclasses 5
values | reporter_country stringclasses 48
values | occr_country stringclasses 46
values | _quarter stringclasses 4
values | age_years float64 0 95 ⌀ | sex_label stringclasses 3
values | reporter_type stringclasses 5
values | report_type stringclasses 5
values | wt_kg float64 2 175 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
231,537,393 | 23,153,739 | 3 | F | null | 20,231,130 | 2023-11-07 | 2023-12-20 | 30DAY | null | US-PFIZER INC-202300331509 | PFIZER | null | 12 | YR | null | M | Y | 86 | KG | 2023-12-20 | null | CN | US | US | 2023Q4 | 12 | Male | Consumer | 30DAY | 86 |
220,523,072 | 22,052,307 | 2 | F | null | 20,230,310 | 2023-03-02 | 2023-04-04 | PER | null | ES-TOLMAR, INC.-23ES038754 | TOLMAR | null | null | null | null | null | Y | null | null | 2023-04-04 | null | HP | ES | ES | 2023Q2 | null | Unknown | Health professional | Periodic | null |
232,953,912 | 23,295,391 | 2 | F | 20,230,101 | 20,231,219 | 2023-12-14 | 2023-12-25 | EXP | null | NL-ABBVIE-5537674 | ABBVIE | null | null | null | E | M | Y | null | null | 2023-12-25 | null | CN | NL | NL | 2023Q4 | null | Male | Consumer | Expedited | null |
218,818,281 | 21,881,828 | 1 | I | null | 20,221,219 | 2023-01-19 | 2023-01-19 | PER | null | US-ABBVIE-22K-163-4342992-00 | ABBVIE | null | null | null | null | F | Y | null | null | 2023-01-19 | null | CN | US | US | 2023Q1 | null | Female | Consumer | Periodic | null |
226,022,531 | 22,602,253 | 1 | I | null | 20,230,609 | 2023-06-14 | 2023-06-14 | PER | null | US-AstraZeneca-2023A135437 | ASTRAZENECA | null | null | null | null | null | Y | null | null | 2023-06-14 | null | MD | US | null | 2023Q2 | null | Unknown | Physician | Periodic | null |
229,948,871 | 22,994,887 | 1 | I | null | 20,230,712 | 2023-09-27 | 2023-09-27 | EXP | null | US-ENDO-CASE-0020081 | ENDO | null | null | null | null | M | Y | null | null | 2023-09-27 | null | CN | US | null | 2023Q3 | null | Male | Consumer | Expedited | null |
218,737,427 | 21,873,742 | 7 | F | null | 20,231,220 | 2023-01-17 | 2023-12-27 | EXP | null | JP-009507513-2301JPN001439J | MERCK | Maruyama S, Yamaguchi H, Takada N, Harayashi T. P-53 Early experience with lenvatinib/pembrolizumab combination therapy.. Journal of Japanese Society of Renal Cancer The 53rd Meeting of Japanese Society. 2023;(53):54 | 69 | YR | null | M | Y | null | null | 2023-12-27 | null | MD | JP | JP | 2023Q4 | 69 | Male | Physician | Expedited | null |
180,284,483 | 18,028,448 | 3 | F | 20,181,101 | 20,231,024 | 2020-07-15 | 2023-11-06 | EXP | null | FR-TAKEDA-2020TUS030335 | TAKEDA | null | 64 | YR | null | F | Y | null | null | 2023-11-06 | null | MD | FR | FR | 2023Q4 | 64 | Female | Physician | Expedited | null |
218,483,281 | 21,848,328 | 1 | I | 20,230,105 | null | 2023-01-10 | 2023-01-10 | DIR | 644137 | null | FDA-CTU | null | 20 | YR | null | F | N | 63 | KG | 2023-01-10 | N | CN | US | null | 2023Q1 | 20 | Female | Consumer | Direct | 63 |
219,992,501 | 21,999,250 | 1 | I | null | 20,230,214 | 2023-02-16 | 2023-02-16 | PER | null | US-SA-2023SA052899 | SANOFI AVENTIS | null | 73 | YR | E | F | Y | null | null | 2023-02-16 | null | CN | US | US | 2023Q1 | 73 | Female | Consumer | Periodic | null |
229,711,471 | 22,971,147 | 1 | I | null | null | 2023-09-21 | 2023-09-21 | DIR | 674804 | null | FDA-CTU | null | null | null | null | UNK | N | null | null | 2023-09-21 | N | CN | US | null | 2023Q3 | null | Unknown | Consumer | Direct | null |
223,867,951 | 22,386,795 | 1 | I | 20,230,523 | 20,230,530 | 2023-05-31 | 2023-05-31 | EXP | null | CL-ABBVIE-5185385 | ABBVIE | null | 18 | YR | null | F | Y | null | null | 2023-05-31 | null | CN | CL | CL | 2023Q2 | 18 | Female | Consumer | Expedited | null |
231,390,861 | 23,139,086 | 1 | I | null | 20,231,031 | 2023-11-02 | 2023-11-02 | EXP | null | ZA-PFIZER INC-202300353831 | PFIZER | null | null | null | null | F | Y | null | null | 2023-11-02 | null | HP | ZA | ZA | 2023Q4 | null | Female | Health professional | Expedited | null |
221,634,101 | 22,163,410 | 1 | I | 20,220,630 | 20,230,322 | 2023-04-01 | 2023-04-01 | EXP | null | EG-ROCHE-3322177 | ROCHE | null | 37 | YR | null | M | Y | null | null | 2023-04-01 | null | CN | EG | EG | 2023Q2 | 37 | Male | Consumer | Expedited | null |
222,801,321 | 22,280,132 | 1 | I | null | 20,230,427 | 2023-05-03 | 2023-05-03 | EXP | null | GB-AMGEN-GBRSL2023074154 | AMGEN | null | 78 | YR | E | M | Y | null | null | 2023-05-03 | null | CN | GB | GB | 2023Q2 | 78 | Male | Consumer | Expedited | null |
232,129,772 | 23,212,977 | 2 | F | 20,231,117 | 20,231,121 | 2023-11-21 | 2023-11-22 | PER | null | US-AMGEN-USASP2023208046 | AMGEN | null | 49 | YR | A | F | Y | null | null | 2023-11-22 | null | CN | US | US | 2023Q4 | 49 | Female | Consumer | Periodic | null |
232,762,891 | 23,276,289 | 1 | I | null | 20,231,205 | 2023-12-08 | 2023-12-08 | PER | null | US-ABBVIE-5529475 | ABBVIE | null | null | null | null | M | Y | null | null | 2023-12-08 | null | CN | US | US | 2023Q4 | null | Male | Consumer | Periodic | null |
226,373,661 | 22,637,366 | 1 | I | null | 20,230,621 | 2023-06-26 | 2023-06-26 | PER | null | US-GLAXOSMITHKLINE-USCH2023030424 | GLAXOSMITHKLINE | null | null | null | null | F | Y | null | null | 2023-06-26 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Periodic | null |
227,037,251 | 22,703,725 | 1 | I | null | 20,230,711 | 2023-07-14 | 2023-07-14 | PER | null | US-SA-2023SA213067 | SANOFI AVENTIS | null | null | null | A | F | Y | null | null | 2023-07-14 | null | MD | US | US | 2023Q3 | null | Female | Physician | Periodic | null |
218,182,011 | 21,818,201 | 1 | I | 20,220,114 | 20,220,131 | 2023-01-04 | 2023-01-04 | EXP | null | US-COOPERSURGICAL, INC.-US-2022CPS000328 | COOPERSURGICAL | null | 36 | YR | null | F | Y | 67.12 | KG | 2023-01-04 | null | HP | US | US | 2023Q1 | 36 | Female | Health professional | Expedited | 67.1 |
222,450,991 | 22,245,099 | 1 | I | 20,230,418 | 20,230,419 | 2023-04-24 | 2023-04-24 | PER | null | US-AMGEN-USASP2023069366 | AMGEN | null | null | null | null | null | Y | null | null | 2023-04-24 | null | HP | US | US | 2023Q2 | null | Unknown | Health professional | Periodic | null |
228,611,892 | 22,861,189 | 2 | F | 20,230,625 | 20,230,825 | 2023-08-24 | 2023-08-28 | EXP | FR-AFSSAPS-PO2023000824 | FR-BIOVITRUM-2023-FR-014167 | BIOVITRUM | null | 90 | YR | null | M | Y | 73 | KG | 2023-08-28 | null | MD | FR | FR | 2023Q3 | 90 | Male | Physician | Expedited | 73 |
225,374,231 | 22,537,423 | 1 | I | 20,020,101 | 20,230,519 | 2023-06-08 | 2023-06-08 | PER | null | US-TEVA-2023-US-2894534 | TEVA | null | 43 | YR | A | F | Y | 122.47 | KG | 2023-06-08 | null | HP | US | US | 2023Q2 | 43 | Female | Health professional | Periodic | 122.5 |
228,324,842 | 22,832,484 | 2 | F | 20,210,301 | 20,230,831 | 2023-08-17 | 2023-09-08 | EXP | null | RU-TEVA-2023-RU-2917128 | TEVA | null | 64 | YR | A | F | Y | null | null | 2023-09-08 | null | HP | RU | RU | 2023Q3 | 64 | Female | Health professional | Expedited | null |
219,603,161 | 21,960,316 | 1 | I | null | 20,230,118 | 2023-02-07 | 2023-02-07 | PER | null | US-ELI_LILLY_AND_COMPANY-US202301008148 | ELI LILLY AND CO | null | null | null | null | F | Y | null | null | 2023-02-07 | null | CN | US | US | 2023Q1 | null | Female | Consumer | Periodic | null |
219,013,141 | 21,901,314 | 1 | I | 20,210,101 | 20,230,109 | 2023-01-23 | 2023-01-23 | EXP | null | US-APOTEX-2023AP001909 | APOTEX | Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, Brown K, Pham Nathaniel PT, Bronstein AC, Weber JA. 2021 Annual Report of the National Poison Data System (NPDS) from America^s Poison Centers: 39th Annual Report. Clinical Toxicology. 2022;60:12:1381-1643 | 55 | YR | null | F | Y | null | null | 2023-01-23 | null | MD | US | US | 2023Q1 | 55 | Female | Physician | Expedited | null |
223,111,191 | 22,311,119 | 1 | I | null | 20,230,509 | 2023-05-11 | 2023-05-11 | PER | null | US-PFIZER INC-PV202300083293 | PFIZER | null | null | null | null | M | Y | null | null | 2023-05-11 | null | MD | US | US | 2023Q2 | null | Male | Physician | Periodic | null |
222,355,461 | 22,235,546 | 1 | I | 20,230,417 | 20,230,418 | 2023-04-20 | 2023-04-20 | PER | null | US-KREUSSLER-2023-US-000121 | CHEMISCHE FABRIK KREUSSLER | null | null | null | null | F | Y | null | null | 2023-04-20 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Periodic | null |
219,098,601 | 21,909,860 | 1 | I | 20,230,117 | 20,230,117 | 2023-01-25 | 2023-01-25 | EXP | null | US-UNITED THERAPEUTICS-UNT-2023-001563 | UNITED THERAPEUTICS | null | 69 | YR | null | F | Y | null | null | 2023-01-25 | null | CN | US | US | 2023Q1 | 69 | Female | Consumer | Expedited | null |
229,759,902 | 22,975,990 | 2 | F | 20,180,326 | 20,231,128 | 2023-09-25 | 2023-12-03 | EXP | null | US-BRISTOL-MYERS SQUIBB COMPANY-USA-20180310423 | BRISTOL MYERS SQUIBB | null | 39 | YR | A | F | Y | null | null | 2023-12-04 | null | MD | US | US | 2023Q4 | 39 | Female | Physician | Expedited | null |
229,190,851 | 22,919,085 | 1 | I | null | 20,230,810 | 2023-09-07 | 2023-09-07 | EXP | null | US-SANDOZ INC.-SDZ2023US024532 | SANDOZ | null | null | null | null | F | Y | null | null | 2023-09-07 | null | MD | US | US | 2023Q3 | null | Female | Physician | Expedited | null |
221,423,842 | 22,142,384 | 2 | F | null | 20,230,321 | 2023-03-27 | 2023-03-31 | EXP | null | US-MYLANLABS-2023M1031496 | MYLAN | Babu S, Prada ZS, Hahn C, Baharloo A, Dini S, Agaram NP, et al. Osteosarcoma as a primary bone tumor in the adult foot: A case report. Foot-Ankle-Surg-(NY) 2022;2:No. 4. | 50 | YR | null | M | Y | null | null | 2023-03-31 | null | MD | US | US | 2023Q1 | 50 | Male | Physician | Expedited | null |
219,969,663 | 21,996,966 | 3 | F | null | 20,230,217 | 2023-02-15 | 2023-02-23 | PER | null | US-AMGEN-USASP2022228834 | AMGEN | null | null | null | null | M | Y | null | null | 2023-02-23 | null | HP | US | US | 2023Q1 | null | Male | Health professional | Periodic | null |
218,926,291 | 21,892,629 | 1 | I | 20,230,113 | 20,230,117 | 2023-01-20 | 2023-01-20 | PER | null | US-PFIZER INC-202300024638 | PFIZER | null | 75 | YR | null | F | Y | null | null | 2023-01-20 | null | CN | US | US | 2023Q1 | 75 | Female | Consumer | Periodic | null |
222,991,933 | 22,299,193 | 3 | F | null | 20,231,214 | 2023-05-09 | 2023-12-19 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-065224 | BRISTOL MYERS SQUIBB | null | 73 | YR | E | M | Y | null | null | 2023-12-20 | null | CN | US | US | 2023Q4 | 73 | Male | Consumer | Periodic | null |
226,222,371 | 22,622,237 | 1 | I | null | 20,230,612 | 2023-06-20 | 2023-06-20 | PER | null | US-JNJFOC-20230628621 | JOHNSON AND JOHNSON | null | null | null | null | null | Y | null | null | 2023-06-20 | null | CN | US | US | 2023Q2 | null | Unknown | Consumer | Periodic | null |
220,778,531 | 22,077,853 | 1 | I | null | null | 2023-03-08 | 2023-03-08 | DIR | FDA-CDER-CTU-2023-18815 | null | FDA-CTU | null | null | null | null | M | N | null | null | 2023-03-08 | N | HP | US | null | 2023Q1 | null | Male | Health professional | Direct | null |
218,301,221 | 21,830,122 | 1 | I | 20,221,222 | null | 2023-01-05 | 2023-01-05 | DIR | FDA-CDER-CTU-2023-1414 | null | FDA-CTU | null | 92 | YR | null | F | N | null | null | 2023-01-05 | N | null | US | null | 2023Q1 | 92 | Female | null | Direct | null |
220,964,351 | 22,096,435 | 1 | I | 20,230,201 | 20,230,309 | 2023-03-15 | 2023-03-15 | EXP | FR-AFSSAPS-PB2023000266 | FR-ROCHE-3305179 | ROCHE | null | 64 | YR | null | F | Y | null | null | 2023-03-15 | null | PH | FR | FR | 2023Q1 | 64 | Female | Pharmacist | Expedited | null |
231,749,301 | 23,174,930 | 1 | I | null | 20,231,107 | 2023-11-12 | 2023-11-12 | EXP | null | US-SANDOZ INC.-SDZ2023US052582 | SANDOZ | Shawn Medford , Abdelwahab Jalal Eldin , Ahmed Brgdar , Lilian Obwolo , Ademola S. Ojo , Constance Mere , Ahmed Al. Beyond the Norm: A Case of Multiorgan InjuryTriggered by Ibuprofen. cureus. 2023;15:11-6 | 71 | YR | null | M | Y | null | null | 2023-11-12 | null | HP | US | US | 2023Q4 | 71 | Male | Health professional | Expedited | null |
227,504,221 | 22,750,422 | 1 | I | null | 20,230,718 | 2023-07-26 | 2023-07-26 | EXP | null | US-AstraZeneca-2023A165276 | ASTRAZENECA | null | null | null | null | F | Y | null | null | 2023-07-26 | null | CN | US | null | 2023Q3 | null | Female | Consumer | Expedited | null |
220,557,943 | 22,055,794 | 3 | F | null | 20,230,530 | 2023-03-02 | 2023-06-01 | PER | null | US-PFIZER INC-PV202300037751 | PFIZER | null | 41 | YR | null | F | Y | null | null | 2023-06-01 | null | HP | US | US | 2023Q2 | 41 | Female | Health professional | Periodic | null |
220,139,681 | 22,013,968 | 1 | I | 20,220,801 | 20,230,213 | 2023-02-21 | 2023-02-21 | EXP | null | US-ROCHE-3285519 | ROCHE | null | 33 | YR | null | F | Y | 69.008 | KG | 2023-02-21 | null | CN | US | null | 2023Q1 | 33 | Female | Consumer | Expedited | 69 |
218,766,741 | 21,876,674 | 1 | I | 20,190,708 | 20,230,110 | 2023-01-18 | 2023-01-18 | EXP | null | FR-CELLTRION INC.-2023FR000490 | CELLTRION | null | null | null | null | null | Y | null | null | 2023-01-18 | null | MD | FR | FR | 2023Q1 | null | Unknown | Physician | Expedited | null |
220,247,491 | 22,024,749 | 1 | I | null | 20,230,220 | 2023-02-23 | 2023-02-23 | PER | null | US-ELI_LILLY_AND_COMPANY-US202302011284 | ELI LILLY AND CO | null | null | null | null | null | Y | null | null | 2023-02-23 | null | CN | US | US | 2023Q1 | null | Unknown | Consumer | Periodic | null |
230,074,181 | 23,007,418 | 1 | I | null | 20,230,712 | 2023-09-29 | 2023-09-29 | EXP | null | US-ENDO-CASE-0026141 | ENDO | null | null | null | null | M | Y | null | null | 2023-09-29 | null | CN | US | null | 2023Q3 | null | Male | Consumer | Expedited | null |
220,684,662 | 22,068,466 | 2 | F | null | 20,230,515 | 2023-03-07 | 2023-05-18 | EXP | null | US-ABBVIE-4329859 | ABBVIE | null | null | null | null | F | Y | null | null | 2023-05-18 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Expedited | null |
220,968,571 | 22,096,857 | 1 | I | 20,230,101 | 20,230,306 | 2023-03-15 | 2023-03-15 | EXP | null | BR-JNJFOC-20230323280 | JOHNSON AND JOHNSON | null | 78 | YR | E | M | Y | null | null | 2023-03-15 | null | CN | BR | BR | 2023Q1 | 78 | Male | Consumer | Expedited | null |
225,188,831 | 22,518,883 | 1 | I | null | 20,230,531 | 2023-06-05 | 2023-06-05 | EXP | null | CA-JNJFOC-20230607675 | JOHNSON AND JOHNSON | null | 68 | YR | E | M | Y | 62 | KG | 2023-06-05 | null | HP | CA | CA | 2023Q2 | 68 | Male | Health professional | Expedited | 62 |
221,987,442 | 22,198,744 | 2 | F | null | 20,230,414 | 2023-04-11 | 2023-04-14 | PER | null | US-PFIZER INC-PV202300064220 | PFIZER | null | null | null | null | null | Y | null | null | 2023-04-14 | null | CN | US | US | 2023Q2 | null | Unknown | Consumer | Periodic | null |
228,815,422 | 22,881,542 | 2 | F | 20,230,808 | 20,230,918 | 2023-08-30 | 2023-09-25 | EXP | null | FR-ROCHE-3412776 | ROCHE | null | 72 | YR | null | F | Y | null | null | 2023-09-25 | null | MD | FR | null | 2023Q3 | 72 | Female | Physician | Expedited | null |
220,528,821 | 22,052,882 | 1 | I | null | 20,230,228 | 2023-03-02 | 2023-03-02 | PER | null | NVSC2023US048209 | NOVARTIS | null | null | null | null | F | Y | null | null | 2023-03-02 | null | MD | US | US | 2023Q1 | null | Female | Physician | Periodic | null |
184,113,273 | 18,411,327 | 3 | F | 20,161,222 | 20,230,911 | 2020-10-21 | 2023-09-14 | EXP | null | US-GILEAD-2020-0500192 | GILEAD | null | 70 | YR | E | M | Y | null | null | 2023-09-14 | null | LW | US | US | 2023Q3 | 70 | Male | Lawyer | Expedited | null |
226,320,371 | 22,632,037 | 1 | I | 20,121,201 | 20,230,617 | 2023-06-23 | 2023-06-23 | EXP | null | US-STRIDES ARCOLAB LIMITED-2023SP009706 | STRIDES | null | null | null | null | null | Y | null | null | 2023-06-23 | null | CN | US | US | 2023Q2 | null | Unknown | Consumer | Expedited | null |
233,182,671 | 23,318,267 | 1 | I | 20,231,201 | 20,231,208 | 2023-12-20 | 2023-12-20 | PER | null | US-SA-2023SA387037 | SANOFI AVENTIS | null | 44 | YR | A | F | Y | null | null | 2023-12-20 | null | MD | US | US | 2023Q4 | 44 | Female | Physician | Periodic | null |
211,137,444 | 21,113,744 | 4 | F | 20,220,101 | 20,230,324 | 2022-07-21 | 2023-04-06 | PER | null | US-KARYOPHARM-2022KPT000731 | KARYOPHARM THERAPEUTICS | null | null | null | null | null | Y | null | null | 2023-04-06 | null | CN | US | US | 2023Q2 | null | Unknown | Consumer | Periodic | null |
219,903,321 | 21,990,332 | 1 | I | null | 20,230,203 | 2023-02-14 | 2023-02-14 | EXP | null | US-GLENMARK PHARMACEUTICALS-2023GMK078803 | GLENMARK | null | null | null | null | null | Y | null | null | 2023-02-14 | null | LW | US | US | 2023Q1 | null | Unknown | Lawyer | Expedited | null |
228,700,481 | 22,870,048 | 1 | I | 20,210,721 | 20,230,814 | 2023-08-27 | 2023-08-27 | EXP | null | PT-AUROBINDO-AUR-APL-2023-054576 | AUROBINDO | null | 62 | YR | null | F | Y | 62 | KG | 2023-08-27 | null | MD | PT | PT | 2023Q3 | 62 | Female | Physician | Expedited | 62 |
165,590,743 | 16,559,074 | 3 | F | null | 20,190,722 | 2019-07-11 | 2023-05-29 | EXP | null | JP-JNJFOC-20190701121 | JOHNSON AND JOHNSON | null | null | null | null | M | Y | null | null | 2023-05-29 | null | PH | JP | JP | 2023Q2 | null | Male | Pharmacist | Expedited | null |
222,545,981 | 22,254,598 | 1 | I | null | 20,230,412 | 2023-04-26 | 2023-04-26 | PER | null | US-JNJFOC-20230451774 | JOHNSON AND JOHNSON | null | 47 | YR | A | F | Y | null | null | 2023-04-26 | null | HP | US | US | 2023Q2 | 47 | Female | Health professional | Periodic | null |
222,388,791 | 22,238,879 | 1 | I | null | 20,230,411 | 2023-04-21 | 2023-04-21 | EXP | null | US-EMD Serono-9395884 | EMD SERONO INC | null | 23 | YR | A | F | Y | null | null | 2023-04-21 | null | MD | US | null | 2023Q2 | 23 | Female | Physician | Expedited | null |
232,139,441 | 23,213,944 | 1 | I | null | null | 2023-11-21 | 2023-11-21 | DIR | FDA-CDER-CTU-2023-85640 | null | FDA-CTU | null | 71 | YR | null | F | N | 245 | LBS | 2023-11-21 | N | null | US | null | 2023Q4 | 71 | Female | null | Direct | 111.1 |
230,488,913 | 23,048,891 | 3 | F | null | 20,231,211 | 2023-10-10 | 2023-12-18 | EXP | null | US-GSK-US2023135723 | GLAXOSMITHKLINE | null | null | null | null | null | Y | null | null | 2023-12-18 | null | CN | US | US | 2023Q4 | null | Unknown | Consumer | Expedited | null |
230,136,451 | 23,013,645 | 1 | I | null | 20,230,921 | 2023-10-01 | 2023-10-01 | PER | null | US-SA-2023SA292809 | SANOFI AVENTIS | null | 66 | YR | E | M | Y | null | null | 2023-10-01 | null | CN | US | US | 2023Q4 | 66 | Male | Consumer | Periodic | null |
219,873,881 | 21,987,388 | 1 | I | null | 20,221,121 | 2023-02-14 | 2023-02-14 | EXP | GB-MHRA-ADR 27479168 | GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2022-13557 | ALKEM | null | null | null | null | M | Y | null | null | 2023-02-14 | null | MD | GB | GB | 2023Q1 | null | Male | Physician | Expedited | null |
217,537,672 | 21,753,767 | 2 | F | null | 20,230,221 | 2022-12-20 | 2023-02-22 | EXP | null | US-INCYTE CORPORATION-2022IN012352 | INCYTE | null | null | null | null | null | Y | null | null | 2023-02-22 | null | MD | US | US | 2023Q1 | null | Unknown | Physician | Expedited | null |
225,282,191 | 22,528,219 | 1 | I | null | 20,230,531 | 2023-06-07 | 2023-06-07 | EXP | null | US-GSK-US2023077188 | GLAXOSMITHKLINE | null | null | null | null | null | Y | null | null | 2023-06-07 | null | CN | US | US | 2023Q2 | null | Unknown | Consumer | Expedited | null |
223,767,342 | 22,376,734 | 2 | F | 20,230,401 | 20,230,519 | 2023-05-28 | 2023-06-05 | EXP | null | CN-ABBVIE-5180811 | ABBVIE | null | null | null | A | null | Y | null | null | 2023-06-05 | null | MD | CN | CN | 2023Q2 | null | Unknown | Physician | Expedited | null |
220,257,721 | 22,025,772 | 1 | I | 20,220,803 | 20,221,207 | 2023-02-23 | 2023-02-23 | EXP | null | US-ROCHE-3154809 | ROCHE | null | 19 | YR | null | F | Y | null | null | 2023-02-23 | null | CN | US | null | 2023Q1 | 19 | Female | Consumer | Expedited | null |
220,309,581 | 22,030,958 | 1 | I | null | 20,230,216 | 2023-02-23 | 2023-02-23 | EXP | null | US-009507513-2302USA005934 | MERCK | McKenney AS, Weg E, Bale TA, Wild AT, Um H, Fox MJ, et al. Radiomic Analysis to Predict Histopathologically Confirmed Pseudoprogression in Glioblastoma Patients. Advances in Radiation Oncology. 2023;8:100916 | null | null | A | null | Y | null | null | 2023-02-23 | null | MD | US | US | 2023Q1 | null | Unknown | Physician | Expedited | null |
228,128,931 | 22,812,893 | 1 | I | 20,221,006 | 20,230,803 | 2023-08-11 | 2023-08-11 | PER | FR-ROCHE-3389361 | FR-Shilpa Medicare Limited-SML-FR-2023-01168 | SHILPA MEDICARE | null | null | null | null | F | Y | null | null | 2023-08-11 | null | HP | FR | FR | 2023Q3 | null | Female | Health professional | Periodic | null |
220,031,791 | 22,003,179 | 1 | I | null | 20,230,206 | 2023-02-17 | 2023-02-17 | PER | null | US-ELI_LILLY_AND_COMPANY-US202302004368 | ELI LILLY AND CO | null | 62 | YR | null | F | Y | null | null | 2023-02-17 | null | CN | US | US | 2023Q1 | 62 | Female | Consumer | Periodic | null |
219,985,641 | 21,998,564 | 1 | I | null | 20,230,214 | 2023-02-16 | 2023-02-16 | EXP | null | CA-MYLANLABS-2023M1001527 | MYLAN | null | null | null | null | M | Y | null | null | 2023-02-16 | null | HP | CA | CA | 2023Q1 | null | Male | Health professional | Expedited | null |
211,345,195 | 21,134,519 | 5 | F | 20,220,501 | 20,230,906 | 2022-07-26 | 2023-09-11 | EXP | null | JP-BRISTOL-MYERS SQUIBB COMPANY-2022-080010 | BRISTOL MYERS SQUIBB | null | 79 | YR | E | M | Y | null | null | 2023-09-12 | null | MD | JP | JP | 2023Q3 | 79 | Male | Physician | Expedited | null |
232,420,801 | 23,242,080 | 1 | I | null | 20,231,120 | 2023-11-29 | 2023-11-29 | EXP | null | FR-MYLANLABS-2023M1125780 | MYLAN | Fauter M, Rossi G, Drissi-Bakhkhat A, Latournerie M, Gerfaud-Valentin M, Durieu I, et al. Hepatic sarcoidosis with symptomatic portal hypertension: A report of 12 cases with review of the literature. Front-Med 2022;9:1-11. | 48 | YR | null | F | Y | null | null | 2023-11-29 | null | HP | FR | FR | 2023Q4 | 48 | Female | Health professional | Expedited | null |
225,876,913 | 22,587,691 | 3 | F | null | 20,230,710 | 2023-06-12 | 2023-07-22 | EXP | null | PT-AUROBINDO-AUR-APL-2023-041367 | AUROBINDO | Andrade MM, Magalhaes RT, Valadas R, Sobral RR, Freire S, Cruz D. Peripheral sensory polyneuropathy secondary to statin. Congressos da Sociedade Portuguesa de Medicina Interna: 29.? Congresso Nacional. 2023 | 38 | YR | null | M | Y | null | null | 2023-07-22 | null | MD | PT | PT | 2023Q3 | 38 | Male | Physician | Expedited | null |
230,399,771 | 23,039,977 | 1 | I | 20,230,831 | 20,230,929 | 2023-10-06 | 2023-10-06 | EXP | null | BR-EMD Serono-2023479316 | EMD SERONO INC | null | 0 | YR | N | F | Y | 3 | KG | 2023-10-06 | null | CN | BR | BR | 2023Q4 | 0 | Female | Consumer | Expedited | 3 |
220,635,081 | 22,063,508 | 1 | I | null | 20,230,228 | 2023-03-06 | 2023-03-06 | PER | null | US-ELI_LILLY_AND_COMPANY-US202303000382 | ELI LILLY AND CO | null | null | null | null | M | Y | null | null | 2023-03-06 | null | CN | US | US | 2023Q1 | null | Male | Consumer | Periodic | null |
221,163,381 | 22,116,338 | 1 | I | null | 20,230,313 | 2023-03-20 | 2023-03-20 | PER | null | US-AMGEN-USASP2023045206 | AMGEN | null | null | null | A | F | Y | null | null | 2023-03-20 | null | MD | US | US | 2023Q1 | null | Female | Physician | Periodic | null |
219,621,281 | 21,962,128 | 1 | I | 20,221,123 | 20,230,201 | 2023-02-07 | 2023-02-07 | EXP | NO-NOMAADVRE-RELISSO-2023-V8d7b7 | NO-MYLANLABS-2023M1012798 | MYLAN | null | 75 | YR | null | F | Y | null | null | 2023-02-07 | null | MD | NO | NO | 2023Q1 | 75 | Female | Physician | Expedited | null |
231,201,101 | 23,120,110 | 1 | I | null | 20,230,713 | 2023-10-29 | 2023-10-29 | EXP | null | US-ENDO-CASE-0036635 | ENDO | null | null | null | null | F | Y | null | null | 2023-10-29 | null | CN | US | null | 2023Q4 | null | Female | Consumer | Expedited | null |
221,930,321 | 22,193,032 | 1 | I | null | 20,230,113 | 2023-04-10 | 2023-04-10 | PER | null | US-THEA-2023000087 | Thea Pharma | null | null | null | null | F | Y | null | null | 2023-04-10 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Periodic | null |
220,997,211 | 22,099,721 | 1 | I | null | null | 2023-03-15 | 2023-03-15 | DIR | FDA-CDER-CTU-2023-20426 | null | FDA-CTU | null | null | null | null | F | N | null | null | 2023-03-15 | N | null | US | null | 2023Q1 | null | Female | null | Direct | null |
222,913,292 | 22,291,329 | 2 | F | null | 20,230,801 | 2023-05-06 | 2023-08-06 | EXP | null | DK-AMGEN-DNKSP2023075938 | AMGEN | Kjaersgaard M.; Andersson N.G.; Lausen B. et al.. Twenty years^ experience of immune thrombocytopenia and intracranial haemorrhage in the Nordic countries-A NOPHO study. Acta Paediatrica. 2023;112 (5):1097-1100 | null | null | null | F | Y | null | null | 2023-08-05 | null | HP | DK | DK | 2023Q3 | null | Female | Health professional | Expedited | null |
197,646,963 | 19,764,696 | 3 | F | 20,130,501 | 20,230,613 | 2021-08-30 | 2023-06-16 | EXP | null | US-GILEAD-2021-0545392 | GILEAD | null | 48 | YR | A | F | Y | 87.982 | KG | 2023-06-16 | null | LW | US | US | 2023Q2 | 48 | Female | Lawyer | Expedited | 88 |
228,797,911 | 22,879,791 | 1 | I | null | 20,230,824 | 2023-08-29 | 2023-08-29 | EXP | null | IE-BAUSCH-BL-2023-012917 | BAUSCH AND LOMB | null | 40 | YR | null | M | Y | null | null | 2023-08-29 | null | MD | IE | IE | 2023Q3 | 40 | Male | Physician | Expedited | null |
223,775,831 | 22,377,583 | 1 | I | 20,220,914 | 20,220,920 | 2023-05-29 | 2023-05-29 | PER | null | ALC2022US004358 | ALCON | null | null | null | null | F | Y | null | null | 2023-05-29 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Periodic | null |
232,661,131 | 23,266,113 | 1 | I | 20,220,924 | 20,221,025 | 2023-12-06 | 2023-12-06 | EXP | null | CA-SANDOZ INC.-NVSC2022CA074400 | SANDOZ | null | 87 | YR | null | F | Y | null | null | 2023-12-06 | null | CN | CA | CA | 2023Q4 | 87 | Female | Consumer | Expedited | null |
229,200,381 | 22,920,038 | 1 | I | null | 20,230,712 | 2023-09-08 | 2023-09-08 | EXP | null | US-ENDO-CASE-0014336 | ENDO | null | null | null | null | M | Y | null | null | 2023-09-08 | null | CN | US | null | 2023Q3 | null | Male | Consumer | Expedited | null |
221,096,952 | 22,109,695 | 2 | F | null | 20,230,507 | 2023-03-17 | 2023-05-08 | PER | null | US-PFIZER INC-PV202300048930 | PFIZER | null | null | null | null | null | Y | null | null | 2023-05-08 | null | HP | US | US | 2023Q2 | null | Unknown | Health professional | Periodic | null |
232,890,671 | 23,289,067 | 1 | I | null | 20,231,208 | 2023-12-12 | 2023-12-12 | EXP | NL-LRB-00930508 | NL-MYLANLABS-2023M1131055 | MYLAN | null | 53 | YR | null | F | Y | 102 | KG | 2023-12-12 | null | CN | NL | NL | 2023Q4 | 53 | Female | Consumer | Expedited | 102 |
231,041,291 | 23,104,129 | 1 | I | 20,230,823 | 20,231,017 | 2023-10-25 | 2023-10-25 | EXP | null | JP-AstraZeneca-2023A240359 | ASTRAZENECA | null | 73 | YR | null | M | Y | null | null | 2023-10-25 | null | MD | JP | null | 2023Q4 | 73 | Male | Physician | Expedited | null |
233,218,351 | 23,321,835 | 1 | I | 20,231,126 | 20,231,214 | 2023-12-20 | 2023-12-20 | EXP | FR-AFSSAPS-PV2023001191 | FR-BRISTOL-MYERS SQUIBB COMPANY-2023-182288 | BRISTOL MYERS SQUIBB | null | 73 | YR | E | F | Y | 71 | KG | 2023-12-20 | null | MD | FR | FR | 2023Q4 | 73 | Female | Physician | Expedited | 71 |
222,691,561 | 22,269,156 | 1 | I | null | 20,230,424 | 2023-05-01 | 2023-05-01 | PER | null | US-ELI_LILLY_AND_COMPANY-US202304013933 | ELI LILLY AND CO | null | null | null | null | F | Y | null | null | 2023-05-01 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Periodic | null |
230,679,341 | 23,067,934 | 1 | I | null | 20,231,011 | 2023-10-16 | 2023-10-16 | EXP | null | US-TAKEDA-2023TUS098848 | TAKEDA | null | null | null | null | F | Y | null | null | 2023-10-16 | null | CN | US | US | 2023Q4 | null | Female | Consumer | Expedited | null |
227,693,851 | 22,769,385 | 1 | I | null | 20,230,726 | 2023-07-31 | 2023-07-31 | PER | null | US-ABBVIE-5345548 | ABBVIE | null | null | null | null | null | Y | null | null | 2023-07-31 | null | CN | US | US | 2023Q3 | null | Unknown | Consumer | Periodic | null |
232,547,601 | 23,254,760 | 1 | I | null | 20,221,220 | 2023-12-03 | 2023-12-03 | EXP | null | US-AMNEAL PHARMACEUTICALS-2022-AMRX-04176 | AMNEAL | null | null | null | null | null | Y | null | null | 2023-12-03 | null | MD | US | US | 2023Q4 | null | Unknown | Physician | Expedited | null |
228,990,941 | 22,899,094 | 1 | I | null | 20,230,712 | 2023-09-04 | 2023-09-04 | EXP | null | US-ENDO-CASE-0011250 | ENDO | null | null | null | null | null | Y | null | null | 2023-09-04 | null | CN | US | null | 2023Q3 | null | Unknown | Consumer | Expedited | null |
221,979,732 | 22,197,973 | 2 | F | 20,220,915 | 20,230,705 | 2023-04-11 | 2023-07-17 | EXP | SE-MPA-2023-001992 | SE-BAYER-2023A043073 | BAYER | null | 31 | YR | A | F | Y | null | null | 2023-07-17 | null | CN | SE | SE | 2023Q3 | 31 | Female | Consumer | Expedited | null |
228,839,926 | 22,883,992 | 6 | F | 20,230,821 | 20,230,915 | 2023-08-30 | 2023-09-17 | EXP | null | JP-BRISTOL-MYERS SQUIBB COMPANY-2023-118123 | BRISTOL MYERS SQUIBB | null | 75 | YR | E | F | Y | null | null | 2023-09-18 | null | HP | JP | JP | 2023Q3 | 75 | Female | Health professional | Expedited | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.